Scientists at the Technical University of Denmark used a hybrid quantum-classical approach to enhance AI models for drug discovery, successfully generating novel peptides for vaccine development. The method showed improved accuracy, especially with limited training data, and could accelerate personalized immunotherapies.
Reed Jobs discusses his oncology-focused venture firm Yosemite, which builds biotech companies from academic research using philanthropy and venture capital. He highlights the firm's progress, the impact of AI on drug discovery and clinical trials, and the potential of targeting previously undruggable genes like p53.
Anthropic is launching an internal drug discovery program focused on neglected diseases, aiming to develop AI tools for drugmakers. The company believes direct experience is crucial for building effective AI solutions for the healthcare industry.
Pramaana Labs announced $27 million in seed funding to apply formal verification tools, inspired by mathematical proofs and the LEAN programming language, to large language models. The startup aims to improve AI reliability in sensitive sectors like law and drug discovery, where errors are costly.
Reid Hoffman leaves Microsoft's board after a profitable decade, including key investments in OpenAI and Inflection AI, to focus on his AI drug discovery startup Manus.
FRONTEO is focusing on identifying target molecules for drug discovery using its AI engine "KIBIT," which analyzes論文 data to find unknown candidates. This accelerates a process that previously took years to mere days, addressing a key bottleneck in AI-driven drug development.
Google DeepMind CEO Demis Hassabis argues companies cutting engineers due to AI productivity gains are misguided. He believes increased efficiency should lead to more ambitious projects, not layoffs, and welcomes laid-off talent for new ventures like drug discovery and game design.
Insilico and Human Longevity partner in a multimillion-dollar AI collaboration to develop personal longevity AI and discover new longevity drugs, as the global longevity market is projected to reach $8 trillion by 2030.
Google DeepMind CEO Demis Hassabis's claim to 'solve all disease' with AI needs context. While AI aids drug discovery, it's a tool, not a magic cure, and breakthroughs take decades. Misinformation risks are high.
China ranked third in a new global index measuring competitiveness in AI for biotechnology, healthcare and longevity, as the race to apply AI moves from chatbots and general-purpose models into regulated, data-heavy industries such as drug discovery, diagnostics and preventive medicine. The latest edition of the Global AI Competitiveness Index, released on Monday by Deep Knowledge Group, a consortium focused on deep-tech research, analytics and investment, ranked China behind only the US and UK...
ByteDance, the Chinese owner of TikTok, is pushing deeper into artificial intelligence with Anew Labs, a drug-discovery unit that has begun presenting its AI-designed therapies at international conferences. The unit – also known as Anew Therapeutics or ByteDance AI Drug Discovery – operates from Shanghai, Singapore and San Jose, California. Its official website listed 36 core members, as well as big names on its “scientific advisory board”: Liu Yongjun, former president of Innovent Biologics, Ji...
Eight mainland China-based companies, including five biotech firms, passed listing hearings on the Hong Kong stock market in April. Metis, founded in 2020 in Hangzhou, uses three proprietary AI platforms to design drug delivery systems. Its revenue surged to 105 million yuan in 2025 from 1.48 million yuan in 2024, while net loss narrowed to 391.8 million yuan. Its leading drug candidate MTS-004 for pseudobulbar affect has completed phase three trials.
GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.
